Systemic Amyloidosis Therapeutic Market powered by growing incidence of amyloidosis diseases
Systemic amyloidosis refers to a group of rare diseases caused by abnormal deposits of amyloid protein scattered systemically throughout the body. The disease can affect various organs including the heart, kidneys, liver, nerves, gastrointestinal tract as well as other tissues. The current treatment options are limited and aims to slow or stop further organ damage. Therapies include drug treatments to reduce the production of amyloid proteins, chemotherapy to suppress plasma cell dyscrasias, and organ transplantation in rare cases.
The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.19 Bn in 2024 and is expected to reach USD 10.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
The growing prevalence of Systemic Amyloidosis Therapeutic globally is a major factor driving the demand for effective therapeutic options. According to the Amyloidosis Research Consortium, the estimated prevalence of systemic amyloidosis is approximately 12-16 cases per million people.
Get more insight on - https://logcla.com/blogs/44460....3/The-Systemic-Amylo